Samrat Pharmachem Q2 FY27: revenue Rs 6,600.86 lakh, PAT Rs 44.11 lakh
Samrat Pharmachem’s standalone Q2 FY27 revenue was Rs 6,600.86 lakh and PAT Rs 44.11 lakh, versus Rs 7,887.03 lakh and loss of Rs (58.71) lakh a year ago.
Key takeaways
- Revenue from operations Rs 6,600.86 lakh vs Rs 7,887.03 lakh in Q2 FY26.
- Total income Rs 6,617.35 lakh vs Rs 7,891.84 lakh a year earlier.
- Total expenses Rs 6,613.01 lakh vs Rs 7,966.66 lakh in the corresponding quarter.
- Profit before tax Rs 4.34 lakh vs loss of Rs (74.82) lakh in Q2 FY26.
- PAT Rs 44.11 lakh vs loss of Rs (58.71) lakh; EPS Rs 1.43 vs Rs (1.90).
Q2 FY27 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 6,600.86 lakh | Rs 7,887.03 lakh | -16.3% |
| PAT | Rs 44.11 lakh | Rs (58.71) lakh | NA |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 0.67% of revenue, up 141 bps from -0.74%.
- Cost of materials accounted for Rs 766.95 lakh of the Rs 1,353.65 lakh fall in total expenses (56%).
- Cost of materials took 99.5% of revenue, against 93.0% a year earlier.
From the statement of standalone unaudited financial results for the quarter ended 30-Sep-26 (Q2 FY27), compared with the corresponding quarter ended 30-Sep-25:
- Revenue from operations: Rs 6,600.86 lakh (Q2 FY26: Rs 7,887.03 lakh)
- Other income: Rs 16.49 lakh (Q2 FY26: Rs 4.81 lakh)
- Total income: Rs 6,617.35 lakh (Q2 FY26: Rs 7,891.84 lakh)
- Cost of material consumed: Rs 6,566.40 lakh (Q2 FY26: Rs 7,333.35 lakh)
- Changes in inventories: Rs (237.05) lakh (Q2 FY26: Rs 381.20 lakh)
- Employee benefits expense: Rs 50.90 lakh (Q2 FY26: Rs 54.69 lakh)
- Finance costs: Rs 8.00 lakh (Q2 FY26: Rs 25.53 lakh)
- Depreciation and amortisation expense: Rs 20.38 lakh (Q2 FY26: Rs 17.85 lakh)
- Other expenses: Rs 204.38 lakh (Q2 FY26: Rs 154.04 lakh)
- Total expenses: Rs 6,613.01 lakh (Q2 FY26: Rs 7,966.66 lakh)
- Profit before tax (before and after exceptional items): Rs 4.34 lakh (Q2 FY26: loss of Rs (74.82) lakh)
- Total tax: Rs (39.77) lakh (Q2 FY26: Rs (16.11) lakh)
- Profit for the year / period (PAT): Rs 44.11 lakh (Q2 FY26: loss of Rs (58.71) lakh)
- Total comprehensive income: Rs 44.11 lakh (Q2 FY26: loss of Rs (58.71) lakh)
- Basic and diluted EPS (Rs): Rs 1.43 (Q2 FY26: Rs (1.90))
In Q2 FY27, standalone revenue from operations of Rs 6,600.86 lakh was lower than the Rs 7,887.03 lakh reported in the corresponding quarter of the previous year, according to the statement of financial results. Total income also declined to Rs 6,617.35 lakh from Rs 7,891.84 lakh over the same period. On the cost side, cost of material consumed reduced to Rs 6,566.40 lakh from Rs 7,333.35 lakh, while changes in inventories moved to Rs (237.05) lakh from Rs 381.20 lakh. Employee benefits expense eased slightly to Rs 50.90 lakh from Rs 54.69 lakh, and finance costs fell to Rs 8.00 lakh from Rs 25.53 lakh. Depreciation and amortisation expense increased to Rs 20.38 lakh from Rs 17.85 lakh, and other expenses rose to Rs 204.38 lakh from Rs 154.04 lakh. Overall, total expenses decreased to Rs 6,613.01 lakh from Rs 7,966.66 lakh.
With lower total income but a sharper reduction in total expenses compared with Q2 FY26, profit before tax turned positive at Rs 4.34 lakh versus a loss of Rs (74.82) lakh a year earlier. The total tax line moved to a credit of Rs (39.77) lakh from Rs (16.11) lakh. As a result, profit for the year / period (PAT) improved to Rs 44.11 lakh from a loss of Rs (58.71) lakh in the corresponding quarter. Basic and diluted EPS similarly moved to Rs 1.43 from Rs (1.90), as shown in the statement of standalone unaudited financial results.
Track Samrat Pharmachem Ltd-$
Cruxal reads every Samrat Pharmachem Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.